A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle

Por Gudde, Anke E. E. G., González-Barriga, Anchel, van den Broek, Walther J. A. A., Wieringa, Bé, Wansink, Derick G.
Publicado no Hum Mol Genet (2016)

CRISPR/Cas9-Induced (CTG⋅CAG)(n) Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing

Por van Agtmaal, Ellen L., André, Laurène M., Willemse, Marieke, Cumming, Sarah A., van Kessel, Ingeborg D.G., van den Broek, Walther J.A.A., Gourdon, Geneviève, Furling, Denis, Mouly, Vincent, Monckton, Darren G., Wansink, Derick G., Wieringa, Bé
Publicado no Mol Ther (2017)

Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy

Por Mulders, Susan A. M., van den Broek, Walther J. A. A., Wheeler, Thurman M., Croes, Huib J. E., van Kuik-Romeijn, Petra, de Kimpe, Sjef J., Furling, Denis, Platenburg, Gerard J., Gourdon, Geneviève, Thornton, Charles A., Wieringa, Bé, Wansink, Derick G.
Publicado em 2009

Cell Membrane Integrity in Myotonic Dystrophy Type 1: Implications for Therapy

Por González-Barriga, Anchel, Kranzen, Julia, Croes, Huib J. E., Bijl, Suzanne, van den Broek, Walther J. A. A., van Kessel, Ingeborg D. G., van Engelen, Baziel G. M., van Deutekom, Judith C. T., Wieringa, Bé, Mulders, Susan A. M., Wansink, Derick G.
Publicado no PLoS One (2015)